組織金屬蛋白酶抑制因子3(TIMP3)活性蛋白
Active Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
SFD; TIMP Metallopeptidase Inhibitor 3; Metallopeptidase Inhibitor 3; Sorsby Fundus Dystrophy; Pseudoinflammatory
- 編號APA129Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 90%
- 等電點9.3
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1426 ¥ 3564 ¥ 7128 ¥ 21384 ¥ 53460
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實驗
Tissue Inhibitors Of Metalloproteinase 3 (TIMP3) is an protein belongs to the tissue inhibitor of metalloproteinases family. They are inhibitors of the?matrix metalloproteinases. TIMP-3 is the only member of the TIMP family which is found exclusively in the extracellular matrix (ECM). It is regulated in a cell cycle-dependent fashion in certain cell types and may serve as a marker for terminal differentiation. The activity of recombinant human TIMP3 was measured by its ability to inhibit recombinant human MMP2 cleavage of a fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2 in the assay buffer 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35 (v/v), pH 7.5. The rhMMP-2 (APA100Hu61) was activated with 1 mM APMA at 37 °C for 1h. Then 16 μl 126 ug/mL rhTIMP-3, 25.6 μL of 100 ug/ml rhMMP-2 and 118.4 μL of assay buffer was incubated for 2 hours at 37 °C, including a control (in duplicate) containing assay buffer and the diluted rhMMP-2. The mixtures was diluted 5 fold in assay buffer followed by adding 50 ul 20 uM substrate, including a control containing assay buffer and substrate. Then read at excitation and emission wavelengths of 320 nm and 405 nm (top read), respectively in kinetic mode for 5 minutes. Under these conditions, the enzyme amount of 50% inhibition of rhMMP-2 activity per minute is defined as a unit. The specific activity of TIMP3 is >6000 U/mg.
Tissue Inhibitors Of Metalloproteinase 3 (TIMP3) is an protein belongs to the tissue inhibitor of metalloproteinases family. They are inhibitors of the?matrix metalloproteinases. TIMP-3 is the only member of the TIMP family which is found exclusively in the extracellular matrix (ECM). It is regulated in a cell cycle-dependent fashion in certain cell types and may serve as a marker for terminal differentiation. The activity of recombinant human TIMP3 was measured by its ability to inhibit rhMMP2 cleavage of a fluorogenic peptide substrate MCA-Pro-Leu-Gly-Leu-DPA-Ala-Arg-NH2 in the assay buffer 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5. rhMMP2 was diluted to 100 ug/ml and activated with 1 mM APMA at 37 °C for 1 hour and rhTIMP3 (MW: 25.28 KD) was diluted to different concentrations with the assay buffer. Mix 8 μl of rhTIMP3 curve dilutions, 12.8 μl of activated rhMMP-2, and 59.2 μl of assay buffer, including a control containing assay buffer and the diluted rhMMP-2 and incubate the reactions for 2 hours at 37 °C. Loading 50?μl of the incubated mixtures which were diluted five-fold in assay buffer into empty wells of a plate, and start the reaction by adding 50?μl of 20?μM substrate. Include a substrate blank containing 50?μl of assay buffer and 50?μl of 20?μM substrate. Then read at excitiation and emission wavelengths of 320 nm and 405 nm, respectively, in kinetic mode for 5 minutes. The result was shown in Figure 1 and it was obvious that recombinant human TIMP3 significantly decreased rhMMP2 activity. The inhibition IC50 was <15 nM.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA129Hu01 | 組織金屬蛋白酶抑制因子3(TIMP3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA129Hu01 | 組織金屬蛋白酶抑制因子3(TIMP3)活性蛋白 | Cell?culture;?Activity?Assays. |
PAA129Hu01 | 組織金屬蛋白酶抑制因子3(TIMP3)多克隆抗體 | WB; IHC; ICC; IP. |
MAA129Hu21 | 組織金屬蛋白酶抑制因子3(TIMP3)單克隆抗體 | WB; IHC; ICC; IP. |
MAA129Hu22 | 組織金屬蛋白酶抑制因子3(TIMP3)單克隆抗體 | WB; IHC; ICC; IP. |
SEA129Hu | 組織金屬蛋白酶抑制因子3(TIMP3)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA129Hu | 組織金屬蛋白酶抑制因子3(TIMP3)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA129Hu | 組織金屬蛋白酶抑制因子3(TIMP3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Neuroimmunomodulation | Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis Virus [Pubmed: source] |
Experimental Biology and Medicine | Acidic pH conditions mimicking degenerative intervertebral discs impair the survival and biological behavior of human adipose-derived mesenchymal stem cells [Rsmjournals: Source] |
PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches [Plosone: Source] |
Physiol. Res. | The unwounded skin remodeling in animal models of diabetes types 1 and 2. [Pubmed: 24020818] |
VirusDisease | Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection [Pubmed:26925446] |
Acta Pharmacol Sin. | Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells. [pubmed:27890915] |
Biochemical genetics | Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancer [pubmed:28421310] |
International Journal of Cancer | Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma [Pubmed: 30650187] |
J. Pers. Med | Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease [Pubmed:35629249] |